RK Ventures Group
VC Fund
New York, United States
RK Ventures Group is a VC fund in New York focused on Health Care and Biotechnology. RK Ventures is a venture capital partnership of individual investors that provides capital and management support to seed and early-stage companies, as well as those that need a bridge to their next round of financing. RK Ventures identifies entrepreneurs who are passionate about their vision and who have the skills and experience to make thatvision a reality. RK has worked with companies across a variety of sectors, though primarily within financial services, software, and biotech.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries RK Ventures Group invests in
Stages RK Ventures Group invests in
Countries RK Ventures Group invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Richard Najuch
|
|||
Investment Focus
Industry
- Health Care 2 (40%)
- Biotechnology 2 (40%)
- Diabetes 1 (20%)
- Hospital 1 (20%)
- Robotics 1 (20%)
Stage
- Series A 2 (40%)
- Series C 1 (20%)
- Series D 1 (20%)
- Funding Round 1 (20%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Richard Najuch
Associate
|
Associate | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Xenex
|
Xenex is offering an effective approach to reducing the incidence of healthcare-associated infections.The Xenex mission is to save lives and reduce suffering by destroying deadly microorganisms that can cause hospital-acquired infections (HAIs). Xenex’s Pulsed Xenon Full Spectrum™ UV Disinfection Solution reduces the bacterial load oftenassociated with an increased risk for HAIs. Since its commercial launch in June 2010, Xenex devices are now included in infection control protocols in almost three hundred hospitals throughout the U.S.Xenex was founded in 2009 and headquartered in San Antonio, Texas. | $25M / Jan 27, 2015 | |
Avid Radiopharmaceuticals
|
Avid develops molecular imaging agents to aid medical management of chronic human diseases. They are located in Philadelphia, PA. Their mission is to develop new molecular imaging agents capable of changing the medical management of significant, chronic human diseases by identifying the first stages of pathological change, potentially assisting inearlier diagnosis, and better management and development of new therapies. | $34.5M / Series D / May 21, 2009 | |
|
Avid Radiopharmaceuticals
|
Avid develops molecular imaging agents to aid medical management of chronic human diseases. They are located in Philadelphia, PA. Their mission is to develop new molecular imaging agents capable of changing the medical management of significant, chronic human diseases by identifying the first stages of pathological change, potentially assisting inearlier diagnosis, and better management and development of new therapies. | $26M / Series C / May 09, 2007 | |
|
Avid Radiopharmaceuticals
|
Avid develops molecular imaging agents to aid medical management of chronic human diseases. They are located in Philadelphia, PA. Their mission is to develop new molecular imaging agents capable of changing the medical management of significant, chronic human diseases by identifying the first stages of pathological change, potentially assisting inearlier diagnosis, and better management and development of new therapies. | $8.9M / Series A / Jan 05, 2006 | |
Redpoint Bio
|
Redpoint Bio is following a strategy focused on preserving the value of the License and Commercialization Agreement it entered into with International Flavors and Fragrances, Inc. (IFF), a global leader in the food and beverage industry. As part of this strategy, the Company continues its efforts to reduce its liabilities and sell its remainingassets. Given its lack of resources, the Company is not currently performing any research and development activities. | $10.2M / Series A / Nov 13, 2003 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does RK Ventures Group invest in?
RK Ventures Group invests primarily in Health Care, Biotechnology and Diabetes startups, most often at Series A and Series C stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact RK Ventures Group?
Public channels for RK Ventures Group include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at RK Ventures Group?
The team at RK Ventures Group includes Richard Najuch (Associate). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
